Company Overview
Charles River Laboratories International, Inc. operates as a comprehensive provider of drug discovery, non-clinical development, and safety testing services, serving clients across the United States, Europe, Canada, the Asia Pacific region, and internationally. The Research Models and Services segment specifically focuses on the production and sale of rodents, as well as purpose-bred rats and mice, supporting the broader research ecosystem. This entity functions within the Healthcare sector, specifically the Diagnostics & Research industry, a domain defined by the critical need for rigorous preclinical data to advance pharmaceutical therapies and medical diagnostics. With a market capitalization of $7.53B and annual revenue of $4.02B, the company demonstrates significant scale supported by an employee base of 18,300. These valuation and revenue figures indicate that Charles River Laboratories is a major player capable of influencing industry standards and maintaining substantial operational reach within the global life sciences supply chain.
Financial Health
The company reported total revenue of $4.02B and EBITDA of $876.57M over the trailing twelve months, while simultaneously reporting a net income of -$144,338,000. The substantial gap between the positive EBITDA and the negative net income reveals a cost structure characterized by significant non-operating expenses, such as interest costs or other general, administrative, and financial charges, that erode bottom-line profitability despite strong core operations. Free cash flow stands at $572.38M, a metric that highlights the company's robust financial flexibility to fund capital expenditures, pursue strategic acquisitions, or manage liquidity without immediate reliance on external financing. Profitability analysis requires examining three distinct margins: a gross margin of 35.0% indicates healthy pricing power and cost control in service delivery, an operating margin of 4.5% suggests moderate efficiency in managing overhead relative to revenue, and a negative profit margin of -3.6% confirms that the company is currently losing money on a net basis. Liquidity and leverage are defined by a cash balance of $213.77M against total debt of $2.63B, resulting in a debt-to-equity ratio of 81.95% which signifies a highly leveraged balance sheet where interest obligations are a primary driver of financial risk. Short-term liquidity is supported by a current ratio of 1.29, indicating the company holds sufficient current assets to cover its current liabilities, though the buffer is not excessively large. Return metrics further illustrate the financial picture, with a return on equity of -4.2% reflecting shareholder dilution from losses, while a return on assets of 4.2% suggests that the asset base is generating positive returns before the impact of financing costs and tax structures.
Valuation Assessment
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative net income, while the forward P/E is 12.49, implying that the market expects a significant turnaround in earnings trajectory over the next twelve months. The price-to-book ratio stands at 2.38, indicating that the market values the company at more than double its book value, which suggests investors are pricing in future growth potential or intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.88 and an EV/EBITDA of 11.41, suggesting the company is trading at a moderate multiple relative to its revenue and earnings before interest, taxes, depreciation, and amortization. Price action over the last year has been volatile, with a 52-week high of $228.88 and a 52-week low of $91.86; assuming the current price context relative to this range, the stock has experienced substantial movement within this band. The stock carries a beta of 1.65, which indicates that its price volatility is significantly higher than the broader market, moving with greater intensity during periods of market stress or rally.
Growth & Income
Growth dynamics are currently constrained, with revenue growth year-over-year declining by 0.8% and earnings growth listed as N/A due to the current loss position. The decline in revenue growth suggests a contraction in the service or model sales volume, while the lack of earnings growth underscores the challenge of converting operational cash flow into net profit under the current leverage structure. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to reinvest into growth initiatives rather than distributing income to shareholders. This strategy aligns with the company's need to strengthen its balance sheet before initiating a dividend, as the current negative net income and high debt-to-equity ratio make a payout unsustainable. The overall growth and income profile is defined by a focus on operational expansion and debt reduction rather than immediate shareholder returns or revenue expansion.